AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02587819
Drug: Treatment with BSCT
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.~Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing.
Trial: NCT01433562
Drug: DLBS1425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
Trial: NCT01433562
Drug: Placebo DLBS1425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
Trial: NCT00464503
Drug: Rosuvastatin-Crestor
RxNorm normalized name: rosuvastatin Oral Tablet [Crestor]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00464503
Drug: Pravastatin-Pravasine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00623870
Drug: RO5045337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses
Trial: NCT04113668
Drug: diflunisal
RxNorm normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified Dose on Specified Days
Trial: NCT01563263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phosphate buffered saline (PBS) solution containing 0,9 % NaCl
Trial: NCT04519463
Drug: Xylocaine Mucosal Product
RxNorm normalized name: Xylocaine Mucosal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylocaine 10% Nasal Spray
Trial: NCT04519463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0.9%
Trial: NCT00575965
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets taken daily
Trial: NCT03077919
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preservative-free normal saline
Trial: NCT02771717
Drug: Placebo - dummy inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - dummy inhaler to be taken 1 puff twice daily.
Trial: NCT04102995
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration
Trial: NCT02798978
Drug: GSK1795091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.
Trial: NCT02798978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be supplied as a solution for injection vial and will be administered as IV bolus over 2-5 min followed by a IV bolus of 10 mL normal saline
Trial: NCT03738618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed.
Trial: NCT00198627
Drug: Co-Trimoxazole; TMP-SMZ
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01080677
Drug: caffeine/propranolol combination tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: caffeine/propranolol combination tablet administered orally once daily
Trial: NCT01080677
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match caffeine/propranolol combination tablet administered orally once daily
Trial: NCT01281540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one placebo tablet 4 times a day for 8 weeks
Trial: NCT00003346
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02089841
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
Trial: NCT02673619
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application.This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm\^2
Trial: NCT01429701
Drug: polymyxin B sulphate + prednisolone + benzocaine + clioquinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied 3 times / day at lesion
Trial: NCT02799212
Drug: placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (50ml of 0.9% NaCl/day) during 6 days.
Trial: NCT01429701
Drug: betamethasone + gentamicin + tolnaftato + cleoquinol
RxNorm normalized name: betamethasone / gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied 3 times / day at lesion
Trial: NCT06630481
Drug: neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.
Trial: NCT01369589
Drug: P-552
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-552 will be administered as 10 mL mouth rinse to be swished in the mouth fro 30 seconds and then completely expectorated.
Trial: NCT01369589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as 10 mL mouth rinse to be swished in the mouth for 30 seconds and then completely expectorated.
Trial: NCT00627367
Drug: Nonprotocolized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An IV opioid the type and dose of which will be determined by the treating clinician
Trial: NCT00680459
Drug: 70% ethanol
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL SPRAY [Anatizer S 70% Ethanol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
Trial: NCT00680459
Drug: heparin flush solution
RxNorm normalized name: heparin Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin flush (10 units/ml) lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. Heparin lock solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
Trial: NCT05122312
Drug: Olinanoseal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: it contains nanometer particles of fluoroapatite and calcium fluoride - guarantees the resistance to cracks and abrasion. At the same time insoluble nano-fluoroapatites fill all enamel microcracks and closes open dentinal tubules.
Trial: NCT01768364
Drug: Trimetoprim-Sulfa (Bactrim)
RxNorm normalized name: Supra Sulfa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04055909
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT05122312
Drug: Curodont D'senz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This agent contains p 11-4 peptide in addition to fluoride
Trial: NCT02018757
Drug: TACE containing As2O3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
Trial: NCT02018757
Drug: TACE containing placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
Trial: NCT02301026
Drug: 5% Iron Isomaltoside 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to local routines and product labeling in doses at the doctors discretion
Trial: NCT02092792
Drug: DLYE5953A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of DLYE5953A
Trial: NCT02092792
Drug: DLYE5953A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of DLYE5953A at the recommended phase II dose (RP2D)
Trial: NCT00536471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00533039
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
Trial: NCT01903018
Drug: P276-00
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02952001
Drug: Sham procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
Trial: NCT02597803
Drug: RGN-259
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
Trial: NCT02597803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4
Trial: NCT02801903
Drug: SB204 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically Once Daily (AM)
Trial: NCT01500850
Drug: nph insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
Trial: NCT06068166
Drug: GDMT
RxNorm normalized name: Guideline-Directed Medical Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patients received maximally tolerated guideline-directed medical therapy (GDMT) alone.
Trial: NCT00140166
Drug: pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02604225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
Trial: NCT00257686
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00992355
Drug: Tobramycin 0.3% - Dexamethasone 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00992355
Drug: Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00711646
Drug: Sativex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Trial: NCT00711646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Trial: NCT03549000
Drug: NIR178
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIR178 Specified dose on specified days, Orally
Trial: NCT00198848
Drug: Iron-folic acid supplement
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01302028
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00402363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00556153
Drug: [F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
Trial: NCT01800357
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion of plabcebo once a day and for 14 days
Trial: NCT01189695
Drug: optimized background regimens (OBRs)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized background regimens such as NRTIs, etravirine or raltegravir
Trial: NCT02454205
Drug: Kanamycin
RxNorm normalized name: Kanamycin
DrugBank: Kanamycin (DB01172)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.
Trial: NCT01685710
Drug: GTN patch
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01685710
Drug: placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm will be a placebo patch to the active drug patch to blind the trial.
Trial: NCT00690625
Drug: MyoRx Cream (6% Omega 3 Fatty Acid)
RxNorm normalized name: Myorx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/2 teaspoon 3 times per day for 30 days.
Trial: NCT00690625
Drug: Placebo cream, no Omega 3 fatty acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream, no Omega 3 fatty acid
Trial: NCT00538304
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye daily for 1 month
Trial: NCT00757055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active treatment given
Trial: NCT00748371
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: one Avicel (cellulose) capsule by mouth twice daily
Trial: NCT03539601
Drug: Hydrocortisone butyrate cream, 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied BID
Trial: NCT00465088
Drug: Niacin ER/Simvastatin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 2000 mg/40 mg at bedtime
Trial: NCT01067144
Drug: Placebo (inactive)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.
Trial: NCT05197517
Drug: Rosuvastatin 10 mg
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film Coated Tablets products containing 10 mg Rosuvastatin
Trial: NCT00973687
Drug: Ora Sweet
RxNorm normalized name: Ora Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A pharmaceutical suspending vehicle and flavouring agent added to the dexamethasone. All arms received the same amount of dexamethasone based on the child's weight, only in different volumes.
Trial: NCT03278028
Drug: A-101 Topical Solution
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-101 Topical Solution
Trial: NCT00568321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03604796
Drug: Rectal Solution
RxNorm normalized name: Rectal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal acetaminophen at 15 mg/kg x 4/day for three days
Trial: NCT03604796
Drug: Intravenous Infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 15 mg/kg IV acetaminophen followed by a continuous infusion at a rate of 2.5 mg/kg/hr for 72 hours
Trial: NCT00225719
Drug: rHDL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00506688
Drug: reduced glutathione sodium salt
RxNorm normalized name: ibuprofen, sodium salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 646 mg GSH-Na powder per vial to prepare a 4ml solution, twice daily for 24 weeks.
Trial: NCT00506688
Drug: 0.9% normal saline (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of a 0.9% normal saline solution (9mg/ml NaCl), twice daily for 24 weeks.
Trial: NCT01053988
Drug: FF/GW642444 Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Trial: NCT01053988
Drug: GW642444 Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long Acting Beta Agonist(LABA)
Trial: NCT01053988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03910712
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
Trial: NCT03058783
Drug: IDP-124 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-124 Lotion, twice-daily application
Trial: NCT00857142
Drug: oxymorphone hydrochloride
RxNorm normalized name: Oxymorphone Hydrochloride
DrugBank: Oxymorphone (DB01192)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02225600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Placebo
Trial: NCT00295867
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid is a new, highly potent, heterocyclic nitrogen-containing third generation bisphosphonate that has demonstrated 40- to 850- fold greater potency than pamidronate in preclinical models of bone resorption. The mechanism of action of nitrogen-containing bisphosphonates such as pamidronate and zoledronic acid appears to involve inhibition of the mevalonate pathway
Trial: NCT02809573
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On Day 1, cyclophosphamide is given in a 20-minute intravenous (IV) infusion at 750 mg/m\^2 in 5 minutes after chidamide administration
Trial: NCT01693081
Drug: VR040/Aspirair® inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry Powder inhaled apomorphine
Trial: NCT01693081
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01137955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally three times a day for 10 days total
Trial: NCT00129623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po monthly for 1 year
Trial: NCT00129623
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg po monthly for 1 year
Trial: NCT00983320
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01839877
Drug: HIA DEBIRI + systemic FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04204408
Drug: NNC0365-3769 (Mim8)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses
Trial: NCT04204408
Drug: Placebo (Mim8)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mim8 placebo administered subcutaneously (s.c., under the skin)
Trial: NCT03334409
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00669487
Drug: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
Trial: NCT00669487
Drug: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
Trial: NCT00669487
Drug: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
Trial: NCT00651638
Drug: Treatment with ARQ 197
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with ARQ 197
Trial: NCT01821378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once Daily
Trial: NCT03643965
Drug: Nefecon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefecon 16 mg for daily administration by mouth for 9 months.
Trial: NCT03643965
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for daily administration by mouth for 9 months.
Trial: NCT00303225
Drug: Vaccine: SIGA-246
FDA approved: no
EMA approved: no
PMDA approved: no